Cantor Fitzgerald Increases Earnings Estimates for Elutia

Elutia Inc. (NASDAQ:ELUT) – Analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Elutia in a report released on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of ($0.65) for the year, up from their prior estimate of ($0.75). Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.74) per share.

Separately, Lake Street Capital cut their price target on shares of Elutia from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, May 9th.

Elutia Price Performance

Shares of NASDAQ:ELUT opened at $1.74 on Wednesday. The company’s fifty day moving average price is $2.44 and its 200 day moving average price is $3.15. Elutia has a 12 month low of $1.68 and a 12 month high of $5.24. The firm has a market capitalization of $70.88 million, a P/E ratio of -0.67 and a beta of 0.97.

Elutia (NASDAQ:ELUT) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $6.03 million for the quarter, compared to analysts’ expectations of $6.65 million.

Institutional Investors Weigh In On Elutia

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. OMERS ADMINISTRATION Corp purchased a new position in Elutia during the 1st quarter worth $28,000. Northern Trust Corp grew its position in Elutia by 30.0% during the 4th quarter. Northern Trust Corp now owns 17,957 shares of the company’s stock worth $67,000 after purchasing an additional 4,148 shares during the last quarter. Arcus Capital Partners LLC purchased a new position in Elutia during the 1st quarter worth $51,000. Citadel Advisors LLC purchased a new position in Elutia during the 4th quarter worth $84,000. Finally, Millennium Management LLC grew its position in Elutia by 16.4% during the 4th quarter. Millennium Management LLC now owns 45,217 shares of the company’s stock worth $169,000 after purchasing an additional 6,386 shares during the last quarter. 74.03% of the stock is currently owned by institutional investors and hedge funds.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.